MedTrace Logo

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

NCT06211023 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2024-01-18

No results posted yet for this study

Summary

This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.

Conditions

Interventions

DRUG

SHR-1921

SHR-1921

DRUG

carboplatin

carboplatin AUC 4

DRUG

carboplatin

carboplatin AUC 5

DRUG

platinum-based doublet chemotherapy

platinum-based doublet chemotherapy

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2026-06-15
Completion
2026-06-15

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06211023 on ClinicalTrials.gov